Biocryst Pharmaceuticals buy Needham & Company LLC
Start price
06.11.23
/
50%
€5.70
Target price
06.11.24
€11.17
Performance (%)
-27.70%
Price
03.05.24
€4.12
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -27.70%. This prediction currently runs until 06.11.24. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Biocryst Pharmaceuticals | 6.102% | 6.102% |
iShares Core DAX® | -0.922% | -1.993% |
iShares Nasdaq 100 | 0.371% | -0.868% |
iShares Nikkei 225® | 2.224% | -5.187% |
iShares S&P 500 | -0.026% | -0.918% |
Comments by Needham___Company_LL for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Needham___Company_LL for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.00
08.01.24
08.01.24
€10.95
08.01.25
08.01.25
-31.32%
03.05.24
03.05.24
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.47
03.08.23
03.08.23
€10.96
03.08.24
03.08.24
-36.27%
03.05.24
03.05.24
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.67
20.04.23
20.04.23
€12.77
20.04.24
20.04.24
-38.50%
21.04.24
21.04.24